

## Special Issue

# Vaccines and Antivirals against Emerging Viruses

### Message from the Guest Editor

A viral disease is considered emerging when it is caused by a novel virus, when it appears for the first time in a specific population, or when the incidence of a known pathogen increases locally or is extended to other local areas. In recent decades many novel infectious diseases have been identified as having been caused by emerging viruses, most of them due to zoonosis. These viruses have been high repercussion in global health, even leading to pandemics, such as the recent example of SARS-CoV-2. In this Special Issue of Vaccines and Antivirals against emerging viruses, we seek research papers contributing to show novel or existing compounds and strategies with potential to prevent or treat viral diseases. In addition, we are interested in papers that describe potential targets to develop antivirals and the molecular methods for diagnosis.

### Guest Editor

Dr. Melissa Belló-Pérez

Department of Molecular and Cell Biology, National Center of Biotechnology (CNB-CSIC), Campus Universidad Autónoma de Madrid, Darwin 3, 28049 Madrid, Spain

### Deadline for manuscript submissions

closed (31 January 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/131139](https://mdpi.com/si/131139)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).